Patents by Inventor Mark Sabat

Mark Sabat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bicyclic pyrazolone cytokine inhibitors
    Publication number: 20050113392
    Abstract: The present invention relates to 6,7-dihydro-5H-pyrazolo[1,2a]pyrazol-1-ones which inhibit the extracellular release of inflammatory cytokines, said cytokines responsible for one or more human or higher mammalian disease states. The present invention further relates to compositions comprising said 6,7-dihydro-5H-pyrazolo[1,2a]pyrazol-1-ones and methods for preventing, abating, or otherwise controlling enzymes which are understood to be the active components responsible for the herein described disease states.
    Type: Application
    Filed: November 5, 2004
    Publication date: May 26, 2005
    Applicant: The Procter & Gamble Company
    Inventors: Michael Clark, Steven Laughlin, Adam Golebiowski, Todd Brugel, Mark Sabat
  • 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
    Patent number: 6849627
    Abstract: The present invention relates to compounds which are capable of preventing the extracellular release of inflammatory cytokines, said compounds, including all enantiomeric and diasteriomeric forms and pharmaceutically acceptable salts thereof, have the formula: wherein R1 is substituted aryl; R4 is substituted or unsubstituted aryl or heteroaryl.
    Type: Grant
    Filed: March 17, 2003
    Date of Patent: February 1, 2005
    Assignee: The Procter & Gamble Company
    Inventors: Michael Philip Clark, Matthew John Laufersweiler, Adam Golebiowski, Mark Sabat, Todd Andrew Brugel
  • 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
    Publication number: 20040038971
    Abstract: The present invention relates to compounds which are capable of preventing the extracellular release of inflammatory cytokines, said compounds, including all enantiomeric and diasteriomeric forms and pharmaceutically acceptable salts thereof, have the formula: 1
    Type: Application
    Filed: March 17, 2003
    Publication date: February 26, 2004
    Applicant: The Procter & Gamble Company
    Inventors: Michael Philip Clark, Matthew John Laufersweiler, Adam Golebiowski, Mark Sabat, Todd Andrew Brugel